Literature DB >> 11515505

MRI features of primary central nervous system lymphomas at presentation.

U Bühring1, U Herrlinger, T Krings, R Thiex, M Weller, W Küker.   

Abstract

Pretreatment MRI examinations of 40 immunologically competent patients with primary CNS lymphoma (PCNSL) were evaluated (24 men, 16 women, median age 63 years). Seventy lesions were found (mean size: 19.9 mm). The number of lesions ranged from one (n = 25) to six (n = 1). The most frequent locations were the cerebral hemispheres (n = 22), the corpus callosum (n = 11), and the basal ganglia (n = 11). Cerebellar manifestations were found in 10 patients. Ocular (n = 2) and medullary cord (n = 1) manifestations were rare. Contrast enhancement was encountered in all lesions. Although 39 patients had lesions adjacent to the CSF space, leptomeningeal spread was only present in five patients. Necrosis was seen in two lesions only. Edema was extensive in 24 patients, moderate in 11 patients, and absent in five patients. Contrast-enhancing lesions in contact with the subarachnoid space and without necrosis are characteristic of PCNSL.

Entities:  

Mesh:

Year:  2001        PMID: 11515505     DOI: 10.1212/wnl.57.3.393

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  54 in total

1.  Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain.

Authors:  R Mangla; B Kolar; T Zhu; J Zhong; J Almast; S Ekholm
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

2.  [Diagnosis of an initial infratentorial central nervous system B-cell lymphoma during prolonged cortisone medication].

Authors:  A Buss; A Assmus; J Weidemann; B Sellhaus; J Lorenzen; F Block
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

3.  Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  Z Xing; R X You; J Li; Y Liu; D R Cao
Journal:  Clin Neuroradiol       Date:  2013-08-31       Impact factor: 3.649

4.  Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.

Authors:  R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna
Journal:  J Neurooncol       Date:  2020-06-10       Impact factor: 4.130

Review 5.  Diagnosis and treatment of primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

6.  Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach.

Authors:  Hie Bum Suh; Yoon Seong Choi; Sohi Bae; Sung Soo Ahn; Jong Hee Chang; Seok-Gu Kang; Eui Hyun Kim; Se Hoon Kim; Seung-Koo Lee
Journal:  Eur Radiol       Date:  2018-04-06       Impact factor: 5.315

Review 7.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

8.  Brain lymphoma: usefulness of the magnetic resonance spectroscopy.

Authors:  Sophie Taillibert; Rémy Guillevin; Carole Menuel; Marc Sanson; Khê Hoang-Xuan; Jacques Chiras; Hugues Duffau
Journal:  J Neurooncol       Date:  2007-09-04       Impact factor: 4.130

9.  Facile synthesis of Gd-doped CdTe quantum dots with optimized properties for optical/MR multimodal imaging.

Authors:  Zizhen Li; Ali Dergham; Holly McCulloch; Yubo Qin; Xiuying Yang; Jingchang Zhang; Xudong Cao
Journal:  J Biol Inorg Chem       Date:  2017-09-01       Impact factor: 3.358

Review 10.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.